Digest Network How does it work
Network
/
Society
Sa
Not verified

Sanofi Winthrop Industrie

What we write about

Foreign PolicyPharmaceuticals

130 Press releases

View all press releases
04/12/2025
Pharmaceuticals
Foreign Policy
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
04/12/2025
Pharmaceuticals
Foreign Policy
Press Release: Sanofi completes acquisition of Vicebio
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
24/11/2025
Pharmaceuticals
Foreign Policy
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
24/11/2025
Pharmaceuticals
Foreign Policy
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
14/11/2025
Pharmaceuticals
Foreign Policy
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
14/11/2025
Pharmaceuticals
Foreign Policy
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
07/11/2025
Pharmaceuticals
Foreign Policy
Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
07/11/2025
Pharmaceuticals
Foreign Policy
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
27/10/2025
Pharmaceuticals
Foreign Policy
Press release: Sanofi successfully prices USD 3 billion of bond issue
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0
27/10/2025
Pharmaceuticals
Foreign Policy
Communiqué de presse : Sanofi place 3 milliards de dollars d’emprunts obligataires
Source
Sanofi Winthrop Industrie
Issuer
GLOBENEWSWIRE
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0